Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 161 entries
View as:

Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02891083 Org: User:
Start: 01/31/16 End: 01/31/21 Due: 01/31/22

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Phase: N/A Priority: Normal
NCT ID: NCT06982924 Org: User:
Start: 06/30/25 End: 12/30/28 Due: 12/30/29

EBUS-GS-TBLB With or Without Fluoroscopy for the Diagnosis of PPLs

Phase: N/A Priority: Normal
NCT ID: NCT01895166 Org: User:
Start: 07/31/13 End: 06/30/14 Due: 06/30/15

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06663306 Org: User:
Start: 11/30/24 End: 11/30/29 Due: 11/30/30

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06173986 Org: User:
Start: 01/10/23 End: 12/30/27 Due: 12/30/28

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04405674 Org: User:
Start: 07/15/20 End: 03/31/25 Due: 03/31/26

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Phase: N/A Priority: Normal
NCT ID: NCT04124731 Org: User:
Start: 10/31/19 End: 04/30/22 Due: 04/30/23

Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan

Phase: N/A Priority: Normal
NCT ID: NCT06358222 Org: User:
Start: 12/15/23 End: 12/31/27 Due: 12/31/28

GGO-dominant PPLs Diagnosis Using CLE and ssRAB-guided Cryobiopsy

Phase: N/A Priority: Normal
NCT ID: NCT06910046 Org: User:
Start: 04/30/25 End: 04/30/27 Due: 04/30/28

Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

Phase: N/A Priority: Normal
NCT ID: NCT06178211 Org: User:
Start: 12/31/23 End: 11/30/26 Due: 11/30/27

Cryoablation vs Thoracoscopic Surgery for GGN

Phase: N/A Priority: Normal
NCT ID: NCT06848881 Org: User:
Start: 04/15/25 End: 04/15/30 Due: 04/15/31

Molecular Analysis and Treatment Options of SCLC

Phase: N/A Priority: Normal
NCT ID: NCT05945745 Org: User:
Start: 01/01/16 End: 12/31/28 Due: 12/31/29

A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)

Phase: N/A Priority: Normal
NCT ID: NCT06709417 Org: User:
Start: 11/01/24 End: 12/31/28 Due: 12/31/29

Driver Ablation of Persistent Atrial Fibrillation With Severe Atrial Fibrosis.

Phase: N/A Priority: Normal
NCT ID: NCT05085912 Org: User:
Start: 11/01/21 End: 10/31/24 Due: 10/31/25

Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Phase: N/A Priority: Normal
NCT ID: NCT06856265 Org: User:
Start: 02/26/25 End: 12/01/25 Due: 12/01/26

Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06962449 Org: User:
Start: 08/16/24 End: 12/31/26 Due: 12/31/27

Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT04870190 Org: User:
Start: 06/01/21 End: 06/01/24 Due: 06/01/25

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

Phase: N/A Priority: Normal
NCT ID: NCT04985851 Org: User:
Start: 09/28/21 End: 12/01/24 Due: 12/01/25

Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)

Phase: N/A Priority: Normal
NCT ID: NCT06385730 Org: User:
Start: 06/17/24 End: 05/31/27 Due: 05/31/28

Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04613284 Org: User:
Start: 12/01/20 End: 08/31/23 Due: 08/31/24

Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06580665 Org: User:
Start: 09/01/24 End: 08/11/30 Due: 08/11/31

To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02977169 Org: User:
Start: 11/30/16 End: 12/31/21 Due: 12/31/22

Catheter Ablation and Surgical Ablation of Persistent Atrial Fibrillation With Severe Atrial Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT05153486 Org: User:
Start: 12/01/21 End: 11/30/24 Due: 11/30/25

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Phase: N/A Priority: Normal
NCT ID: NCT04504071 Org: User:
Start: 12/08/20 End: 12/31/22 Due: 12/31/23

Transthoracic vs Transbronchial Ablation for Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06503744 Org: User:
Start: 01/04/24 End: 12/31/28 Due: 12/31/29